Here’s what you should know.
1. Shire creates pharmaceutical treatments for rare diseases and hyperactivity.
2. The rumors sent Shire’s stock price rocketing. The drug maker’s stock rose 25 percent March 27.
3. Shire is valued at $46.3 billion (£32.7 billion).
4. Takeda confirmed to CNBC its approach was at a preliminary and exploratory stage. Takeda will have until April 25 to make a bid.
More articles on coding, billing and collections:
Readers push back on ‘sensationalized’ story misrepresenting ASC safety — 5 insights
3 ways ASCs can capitalize on the transition to outpatient care
Drugmaker paid roughly $550K to lobby for ASC, outpatient reimbursement status
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
